


SS-RJW100

Cat. No.:	HY-131445A		
Molecular Formula:	C ₂₈ H ₃₄ O		
Molecular Weight:	386.57		
Target:	Others		
Pathway:	Others		
Storage:	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (258.69 mM; Need ultrasonic)

Concentration	Solvent	Mass	1 mg	5 mg	10 mg
			Concentration	1 mg	5 mg
1 mM			2.5869 mL	12.9343 mL	25.8685 mL
5 mM			0.5174 mL	2.5869 mL	5.1737 mL
10 mM			0.2587 mL	1.2934 mL	2.5869 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

SS-RJW100 is an enantiomer of RJW100, which is a racemic agonist of nuclear receptor liver receptor homolog 1 (LRH-1) and steroidogenic factor 1 (SF-1). SS-RJW100 promotes recruitment of coregulator protein fragments in vitro, recruits the transcriptional intermediary factor 2 (Tif2) coactivator to LRH-1. SS-RJW100 diminishes LRH-1 allosteric activation networks, shows poor thermal stability^{[1][2]}.

IC₅₀ & Target

Ki: 1.2 μM (LRH-1), 30 μM (SF-1)^[1]

In Vitro

Liver receptor homolog-1 (LRH-1) and steroidogenic factor-1 (SF-1) are closely related nuclear hormone receptors (NR) that play key roles as regulators of metabolism, inflammation, and proliferation^[1]. SS-RJW100 (1 nM-1 mM;) binds LRH-1 and SF-1, with binding affinity K_i values of 1.2 μM (LRH-1), 30 μM (SF-1), respectively^[1]. SS-RJW100 (30 μM; 24 h) increases LRH-1 transcriptional activity in both wild-type and mutant LRH-1 overexpressed Hela cells, without being affected by mutations^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[1]

Cell Line: Wild-type (WT) and mutant LRH-1 overexpressed Hela cells (T352V, H390A, A349F)

Concentration:	30 μ M
Incubation Time:	24 hours; for pre-treatment
Result:	Increased increases LRH-1 transcriptional activity. Showed activation effect on LRH-1 expressing cells without being affected by T352V LRH-1 mutant or H390A LRH-1 mutant.

REFERENCES

[1]. Mays SG, et al. Enantiomer-specific activities of an LRH-1 and SF-1 dual agonist. Sci Rep. 2020 Dec 17;10(1):22279.

[2]. Stec J. Tandem reaction sequences on a zirconocene template[J]. University of Southampton, 2010.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA